Savara Inc. (NASDAQ:SVRA) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Savara Inc. has received a consensus rating of "Moderate Buy" from six analysts, with five giving it a buy rating and one a hold rating.
• Analysts have set an average price target of $7.50 for the stock, with recent upgrades from Guggenheim to $11.00 and Oppenheimer to $8.00.
• Institutional investors own 87.93% of Savara's stock, indicating strong institutional confidence in the company.

Savara Inc. (NASDAQ:SVRA - Get Free Report) has earned a consensus rating of "Moderate Buy" from the six analysts that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $7.50.

Several analysts have weighed in on SVRA shares. Guggenheim upped their price objective on shares of Savara from $8.00 to $11.00 and gave the stock a "buy" rating in a research note on Tuesday, September 9th. Oppenheimer increased their price target on Savara from $6.00 to $8.00 and gave the stock an "outperform" rating in a research report on Monday, September 8th. Finally, HC Wainwright lifted their price objective on Savara from $5.00 to $8.00 and gave the company a "buy" rating in a research report on Wednesday, September 3rd.

Savara Stock Performance

Shares of NASDAQ:SVRA opened at $3.49 on Friday. The company has a debt-to-equity ratio of 0.25, a current ratio of 11.08 and a quick ratio of 11.08. The business's fifty day moving average price is $3.20 and its two-hundred day moving average price is $2.84. Savara has a fifty-two week low of $1.89 and a fifty-two week high of $4.30. The stock has a market capitalization of $603.21 million, a price-to-earnings ratio of -6.98 and a beta of 0.46.

Savara (NASDAQ:SVRA - Get Free Report) last issued its earnings results on Wednesday, August 13th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.02). As a group, analysts predict that Savara will post -0.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Savara

A number of hedge funds have recently added to or reduced their stakes in the stock. Ameriprise Financial Inc. acquired a new stake in Savara in the 4th quarter valued at about $37,000. Prudential Financial Inc. bought a new stake in shares of Savara during the second quarter valued at approximately $30,000. BNP Paribas Financial Markets increased its holdings in shares of Savara by 52.3% in the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company's stock valued at $31,000 after purchasing an additional 4,626 shares in the last quarter. May Hill Capital LLC bought a new position in Savara in the 2nd quarter worth approximately $32,000. Finally, Brevan Howard Capital Management LP bought a new position in Savara in the 2nd quarter worth approximately $33,000. Institutional investors own 87.93% of the company's stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.